PF 07941314
Alternative Names: PF-07941314; RSVpreF + qIRVLatest Information Update: 08 Sep 2023
At a glance
- Originator Pfizer
- Class Influenza virus vaccines; Respiratory syncytial virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Influenza virus infections; Respiratory syncytial virus infections
Most Recent Events
- 09 Mar 2023 Phase-I clinical trials in Influenza virus infections (Prevention, In adults, In the elderly) in Argentina (Parenteral) (NCT05788237)
- 09 Mar 2023 Phase-I clinical trials in Respiratory syncytial virus infections (Prevention, In adults, In the elderly) in Argentina (Parenteral) (NCT05788237)